Background: Patients with renal infarction are vulnerable to thromboembolic complications with poor outcomes. There is limited report concerning the effect of anti-coagulant therapy in this population. Aim: To assess the impact of anti-coagulant therapy on outcomes in patients with renal infarction. Design: A retrospective cohort study of 101 renal infarction patients was conducted. Methods: The association between anti-coagulant therapy, all-cause mortality, thromboembolic complications and renal outcome was evaluated. Demographic data and comorbidities were collected for analysis. Anti-coagulant therapy was treated as a time-dependent variable. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariate Cox proportional hazards models. Results: Fifty-seven (56.4%) patients with renal infarction received anti-coagulant therapy during the study period. The allcause mortality rate was 7.56 per 100 patient-years. Age (HR 1.05, 95% CI 1.02-1.08) was a risk factor for all-cause mortality and anti-coagulant therapy was associated with a 92% improved survival (HR 0.08, 95% CI 0.02-0.34). Twelve (11.9%) thromboembolic events occurred following renal infarction. Current smoking (HR 10.37, 95% CI 1.60-67.43) had an adverse effect and anti-coagulant therapy (HR 0.14, 95% CI 0.03-0.73) had a significant protective impact on thromboembolic complications. There was no significant association between anti-coagulant therapy and long-term renal outcome in renal infarction patients including the monthly change in the estimated glomerular filtration rate (eGFR), the incidence of eGFR reduction of more than 50% and end-stage renal disease. Conclusion: Anti-coagulant therapy in patients with renal infarction was associated with better survival and reduced thromboembolic complications.
Introduction
Renal infarction (RI) results from an abrupt disruption of renal blood flow causing ischemic damage of renal parenchyma.
The incidence of RI based on emergency department studies ranged from 0.004% to 0.013% which might be underestimated owing to its non-specific presentation. [1] [2] [3] The interruption of renal blood flow in RI is attributed to in situ thrombosis or thromboemboli from heart or aorta. Patients with RI have increased risk of thromboembolic complications and renal function deterioration because of pathophysiology underlying RI or comorbidities such as atrial fibrillation or diffuse atherosclerotic disease. [4] [5] [6] [7] [8] [9] It is reported that 34.6% of patients developed thromboembolic events following RI and the 30-day mortality rate was 11.4%. 10 One recent study showed that 20.1% of RI patients had acute kidney injury (AKI), 10 .9% progressed to chronic kidney disease, 2.1% reached end-stage renal disease (ESRD) and 5% died during the initial admission. 11 Long-term survival of patients with RI is undetermined. The use of anti-coagulant therapy in RI is aimed to decrease mortality through preventing thromboembolic complications. However, patients receiving anti-coagulant therapy may increase the risk of morbidity and mortality associated with hemorrhage. In addition, anti-coagulant related acute kidney injury has been proposed recently as a potential adverse effect in patients being treated with warfarin or dabigatran. [12] [13] [14] [15] Previous case series revealed that 44.7% to 87.7% of patients with RI received anti-coagulant therapy. [9] [10] [11] Up to now, the impact of anti-coagulant therapy on outcomes in patients with RI remains uncertain.
In this work, we conducted a cohort study to evaluate the association between anti-coagulant therapy, all-cause mortality, thromboembolic complications and renal outcome in patients with RI. We hypothesized that the use of anti-coagulant therapy in RI patients would decrease the risk of all-cause mortality and thromboembolic complications, and preserve residual renal function.
Materials and methods

Study design and patient population
A cohort study was conducted between 1 October 1991 and 31 May 2016. Patients with radiologic evidence of RI were enrolled. Patients younger than 20 years and those who presented with RI after receiving vascular surgery, percutaneous transluminal angioplasty or a kidney transplant were excluded. The study complied with the Declaration of Helsinki principles and was approved by the Institutional Review Board of Kaohsiung Veterans General Hospital (VGHKS17-CT5-01).
Baseline demographic and comorbid characteristics
Demographic data and underlying comorbid conditions, including hypertension, diabetes mellitus, hyperlipidemia, atrial fibrillation, coronary artery disease, congestive heart failure, valvular heart disease, cerebrovascular accident and peripheral arterial occlusive disease were collected for each patient when enrollment. Current smoking was defined as any cigarette use in the past 30 days. Previous anti-coagulant therapy was defined as receiving anti-coagulant therapy within the past 3 months. Anti-platelet therapy after RI was recorded.
Clinical presentation and laboratory findings
Clinical manifestations, laboratory data and radiologic imaging findings were recorded. The estimated glomerular filtration rate (eGFR) was measured by the Modification of Diet in Renal Disease Study equation. 16 Microscopic hematuria was defined as more than three red blood cells per high-power field. Proteinuria was defined as positive by dipstick. The kidney volume and RI size were assessed in patients with available CT images. The ellipsoid formula using three-dimensional values of the kidney was used to estimate the kidney volume.
17-19
Anti-coagulants exposure assessment Anti-coagulant therapy was defined as intravenous heparin administration, intravenous heparin followed by oral anti-coagulant medication, or oral anti-coagulant medication alone. Patients who had been treated with anti-coagulant therapy after RI were defined as anti-coagulant users; the remaining patients were defined as anti-coagulant non-users. Anti-coagulant therapy was treated as a time-dependent variable. Anti-coagulant therapy exposure time was defined as the period from the first date of anticoagulation until the end date of therapy.
Outcomes
The primary endpoints were time to all-cause mortality, time to the first thromboembolic event following RI and long-term renal outcome. Thromboembolic events comprised ischemic stroke, myocardial or other organ infarction, recurrent RI and peripheral arterial occlusive disease. Renal function was evaluated at four points including T1, within 1 year before RI, T2, at the onset of RI, T3, within 3 months after RI and T4, 3 months after RI. AKI was defined by an increase in the serum creatinine level of 0.3 mg/dl or more within 48 h or an increase in the serum creatinine by at least 1.5 times the baseline value. 20 Long-term renal outcome was evaluated in patients who had at least one post-discharge measurement of eGFR level including the change in the eGFR over time, the incidence of eGFR reduction of more than 50%, and the incident ESRD. ESRD was defined by receiving maintenance dialysis. For the safety assessment of anti-coagulant therapy, intracranial hemorrhage (ICH) was recorded. Data were obtained from medical records. All patients were followed until death, lost follow-up, or 31 May 2016.
Statistical analyses
Data were presented as mean 6 SD, median (interquartile range), or number (percentage), as appropriate. Baseline and clinical characteristics and long-term renal outcome were compared between the anti-coagulant users and non-users using chi-square tests for categorical variables, independent Student's t-tests for normally distributed continuous variables and Mann-Whitney U-tests for skewed continuous variables. The association between anti-coagulant therapy and all-cause mortality was estimated using the Kaplan-Meier procedure. To assess the influence of risk factors on all-cause mortality and thromboembolic complications, univariate and multi-variate Cox proportional hazards models were performed. [21] [22] [23] In the multi-variable models for all-cause mortality, analyses were adjusted for age, sex, anti-coagulant therapy, hypertension, diabetes mellitus, atrial fibrillation, coronary artery disease and cerebrovascular accident. In the multi-variable models for thromboembolic complications, covariates mentioned above plus current smoking, hyperlipidemia and valvular heart disease were adjusted. Anti-coagulant therapy was included as a timedependent variable to avoid immortal time bias. 24 The multivariate binary and linear logistic regression were applied to test the correlation between RI size and AKI, and the correlation between RI size and the change in the eGFR over time. 25 The association between RI size and all-cause mortality was assessed using multivariate Cox proportional hazards models with adjustment for covariates mentioned above plus RI size per total kidney volume. Sensitivity analysis was conducted to test the reliability of our findings. For sensitivity analysis, we defined anti-coagulant therapy exposure time as the period from the first prescription date to 5 days after anti-coagulant therapy because the anti-coagulant effect in most patients vanished 5 days after holding anti-coagulant therapy. 26 We restricted the analysis to patients without previous anti-coagulant therapy and those without active malignancy, anti-phospholipid syndrome, endocarditis, renal artery dissection or trauma to reduce the heterogeneity of the study population. All covariates mentioned above except hyperlipidemia were adjusted in the multi-variate models for all-cause mortality and thromboembolic complications. All P-values were two-sided, and the significance level was set at 0.05. All statistical analyses were performed using SPSS 22.0.0 (SPSS Inc., Chicago, IL).
Results
Characteristics of patients
One hundred and one patients with RI were included in this study ( Figure 1 ). The diagnosis of RI was made mostly by computed tomography, and two by renal angiography. Fifty-seven (56.4%) patients received anti-coagulant therapy, while fortyfour patients did not. Of the 57 anti-coagulant users, 44 (77.2%) received intravenous heparin followed by oral warfarin, 7 were treated with oral warfarin alone and 6 were administered intravenous heparin alone. Warfarin was switched to rivaroxaban in two patients ever been treated with intravenous heparin. Table 1 shows the baseline characteristics of included patients. The proportion of previous anti-coagulant therapy and the prevalence of atrial fibrillation and valvular heart disease were higher in anti-coagulant users. The cause that patients with atrial fibrillation did not receive anti-coagulant therapy was concurrent gastrointestinal bleeding in two cases, unstable vital sign in two cases, recent intracranial hemorrhage in one case, bleeding diathesis in one case and CHA2DS2-VASc score of 0 in one case. Other baseline characteristics and the proportion of anti-platelet therapy after RI did not differ between the two groups. Clinical manifestations, laboratory data and radiologic image findings are summarized in Table 2 . Abdominal or flank pain was the more frequent symptom, and fever was the less frequent clinical manifestation in anti-coagulant users. Both laboratory data and radiologic image finding were similar between the two groups. Anti-coagulant users had higher RI size and size ratio than anti-coagulant non-users.
Anti-coagulant therapy and outcomes
During the mean follow-up of 48 months, there were 12 deaths (four due to infection, three to intracranial hemorrhage, two to ischemic stroke, one to ischemic bowel, one to heart failure, one to sudden death) among anti-coagulant users (4.57 per 100 patient-years) compared with 18 deaths (five to infection, two to ischemic stroke, one to ischemic bowel, two to heart failure, one to sudden death, one to ventricular fibrillation, three to malignancy, three to aortic dissection) among anti-coagulant non-users (13.40 per 100 patient-years, P ¼ 0.01; Figure 2 ). We evaluated the influence of risk factors on all-cause mortality ( Anti-platelet therapy was defined as receiving anti-platelet therapy after renal infarction.
adjustment, age (HR 1.05, 95% CI 1.02-1.08) was significantly associated with an increased risk of all-cause mortality. Anticoagulant therapy (HR 0.08, 95% CI 0.02-0.34) was independently associated with a decreased risk of all-cause mortality.
The effect of anti-coagulant therapy on thromboembolic complications was investigated. Eight thromboembolic events (four ischemic strokes, one ischemic bowel, one peripheral arterial occlusive disease, one splenic infarction, one recurrent RI) occurred among anti-coagulant users compared with four events (three ischemic strokes and one acute myocardial infarction) among anti-coagulant non-users. As shown in Table 4 , current smoking (HR 10.37, 95% CI 1.60-67.43) was a significant adverse factor, and anti-coagulant therapy (HR 0.14, 95% CI 0.03-0.73) was a significant protective factor for thromboembolic complications in the multi-variate analysis. Additionally, we conducted sensitivity analysis to test the reliability of our findings. Anti-coagulant therapy exposure time was defined as the period from the first prescription date to 5 days after anti-coagulant therapy. Anti-coagulant therapy remained a significant protective factor for all-cause mortality (HR 0.23, 95% CI 0.08-0.65) and thromboembolic complications (HR 0.14, 95% CI 0.03-0.73). The protective effect of anti-coagulant therapy on all-cause mortality and thromboembolic complications was similar in 88 patients without previous anticoagulant therapy (HR 0.11, 95% CI 0.02-0.53 and HR 0.02, 95% CI 0.001-0.58, respectively). Moreover, we restricted the analysis to 76 patients after excluding three patients with active malignancy, one with anti-phospholipid syndrome, ten with endocarditis, four with renal artery dissection and seven with trauma. The multi-variate analysis indicated that anti-coagulant therapy remained an independent protective factor for all-cause mortality and thromboembolic complications (HR 0.11, 95% CI 0.02-0.50 and HR 0.14, 95% CI 0.02-0.79, respectively).
The short-term serial change of renal function from the onset of RI to 3 months after RI is similar between anti-coagulant users and non-users (Figure 3) . The incidence of AKI during the initial admission was similar between two groups (15.8% vs. 25%, P ¼ 0.25). No patients received renal replacement therapy during the initial admission. Long-term renal outcome was evaluated among 70 patients (47 anti-coagulant users and 23 anti-coagulant non-users). The monthly change in the eGFR was À0.76 ICH was recorded in three anti-coagulant users during follow-up period. The mean age was 74 years. Among them, one patient with history of Child C cirrhosis and multiple falls had subdural hemorrhage. The international normalized ratio (INR) at the time of diagnosis was 2.5. The other two patients had ICH with apparent prolonged INR (7.9 and greater than 10, respectively). All three patients died within 1 week. There was no anticoagulant related AKI reported.
Discussion
The current study indicates that the use of anti-coagulant therapy in patients with RI was associated with a decrease in allcause mortality and thromboembolic complications. The major causes of death in the study were due to thromboembolic or cardiovascular events (60%). RI patients are vulnerable to thromboembolic complications and our result is compatible with the study by Caravaca-Fontá n et al., showing a reduction in mortality in RI patients treated with anti-coagulants 27 within 6 months. The follow-up period of 48 months in our study was longer, in which the long-term effect of anti-coagulant therapy on survival could be represented. Moreover, with sensitivity analysis, the protective effect of anti-coagulant therapy on mortality remained, which reinforce the association between anticoagulant therapy and better survival in RI patients. Our study suggests that anti-coagulant therapy was independently associated with a decrease in thromboembolic complications. In the study, 11.9% of patients developed thromboembolic events and the predominant thromboembolic complication was ischemic stroke (58.3%), which is consistent with the study by Hazanov et al. 10 Anti-coagulant therapy is usually indicated when RI patients had atrial fibrillation although the efficacy is uncertain. In addition, the effect of anticoagulant therapy on thromboembolic complications in idiopathic RI patients and patients without atrial fibrillation remains elusive. [9] [10] [11] Our result demonstrated that anti-coagulant therapy had an independent protective impact on thromboembolic complications in RI patients and the protective effect was consistent when patients with active malignancy, endocarditis, renal artery dissection or trauma were excluded. Taken together with the finding of association between anti-coagulant therapy and all-cause mortality, we suppose that, the significant reduction of thromboembolic complications in RI patients receiving anti-coagulant therapy is the possible mechanism of the survival benefit. Anti-coagulant therapy may preserve the residual renal function through decreasing the risk of repeated RI. A trend of better renal prognosis in RI patients with early diagnosis and anti-coagulant therapy had been proposed. 28 Our results
showed that anti-coagulant users had a non-significant trend toward better long-term renal outcome. The results are reasonable, since, there is only one recurrent RI during follow-up. The compensatory hypertrophy in the remaining kidney may also limit long-term deterioration in renal function. Assessing by stratification 29, 30 or reconstructed computed tomography, 25 the association of RI size and renal function is undetermined. Though our results showed that RI size was not associated with renal outcome, and all-cause mortality, the measurement bias of assessing RI size existed. Further studies are needed to test the hypothesis. The major safety concern of anti-coagulant therapy is the risk of hemorrhage, especially ICH. ICH leads to nearly 90% of deaths from warfarin-associated hemorrhage and most of the permanent disability. [31] [32] [33] [34] In our study, three anti-coagulant users suffering from ICH had risk factors of anti-coagulant therapy associated hemorrhage including aging, prolonged INR and cirrhosis. [32] [33] [34] Care must be taken to reduce the catastrophic complication during anti-coagulant therapy. [12] [13] [14] [15] 33, 34 . In addition, warfarin-related nephropathy [12] [13] [14] [15] defined by an increase in the serum creatinine of 0.3 mg/dl or more within 1 week of an INR greater than 3.0 in a patient receiving warfarin therapy without clinical evidence of hemorrhage is associated with increased risk of AKI and mortality in patients with chronic kidney disease. 13 In our study, two patients treated with warfarin developed AKI after discharge and had prolonged INR with level greater than 3.0. However, there were certified causes of AKI in these two patients. Although no report in our cohort, physicians should carefully monitor renal function in patients with anticoagulant therapy to avoid the possible adverse effect. Several limitations of our study must be acknowledged. The minor and clinically insignificant thromboembolic events might be missed. However, the thromboembolic events contributing to death equate to diseases requiring hospital admission and are the issues we concerned. Evaluation of the incidence of major thromboembolic events in this study was unlikely to be underestimated. Deaths unrelated to thromboembolic or cardiovascular events may hamper the interpretation about the association between anti-coagulant therapy, all-cause mortality and thromboembolic complications. The association between anti-coagulant therapy and the bleeding risk other than ICH was not investigated.
In summary, the use of anti-coagulant therapy in patients with RI was associated with better survival and a decrease in thromboembolic complications. Our findings highlight the importance of anti-coagulant therapy in RI patients and close monitoring of RI patients for better clinical outcomes.
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